Emerging Anti-Angiogenesis Therapies in Pleural Mesothelioma

This webcast is based on a roundtable discussion among three key opinion leaders as they exchange their views on the promise of emerging anti-angiogenesis therapies in malignant pleural mesothelioma (MPM). The experts will review the latest clinical trial data, examine outcomes in histological subgroups of MPM, and consider how the novel data relates to clinical practice. Future directions in MPM treatment and advances in combination treatment strategies in which anti-angiogenics are combined with chemotherapy and/or immunotherapy will be discussed.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with MPM.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be better able to:

  1. Summarize clinical trials with angiokinase inhibitors.
  2. Review the value of novel angiokinase inhibitors for the treatment of patients with MPM.
  3. Outline the advantages of combining an angiokinase inhibitor with chemotherapy or immunotherapy for treatment of patients with MPM.
  4. Reflect on the future of MPM treatment.

FACULTY

David J. Sugarbaker, MD
Baylor College of Medicine, Lung Institute, and Division of Thoracic Surgery
Baylor St. Luke’s Medical Center
Houston, TX, USA
Anne S. Tsao, MD
University of Texas MD Anderson Cancer Center
Houston, TX, USA
Jun Zhang, MD
Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Houston, TX, USA

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:

David J. Sugarbaker, MD

No conflicts of interest

Anne S. Tsao, MD

Consultant/Advisor: ARIAD Pharmaceuticals, Inc., AstraZeneca, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Eli Lilly and Company, EMD Serono, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Merck & Co., Inc, Novartis AG, Seattle Genetics, Inc., Sellas

Grant/Research Support: ARIAD Pharmaceuticals, Inc., AstraZeneca, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Epizyme®, Inc., Genentech Inc., Merck & Co., Inc, Polaris Pharmaceuticals, Inc., Seattle Genetics, Inc.

Jun Zhang, MD

No conflicts of interest

Non-faculty: Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Marijke Verhaaf, Joke Artmanni, Elena Knoche, PhD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Boehringer Ingelheim.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Excerpta Medica.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Excerpta Medica. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 CreditTM issued by organizations accredited by the Accreditation Council for Continuing Medical Education (ACCME) for the purpose of reaccreditation for both nurse practitioners and registered nurses

The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 CreditTM issued by organizations accredited by the ACCME for Category 1 CME credit activities for physician Assistants

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Excerpta Medica, and Boehringer Ingelheim do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician
Course opens: 
03/01/2018
Course expires: 
02/28/2019
Rating: 
0

Available Credit

  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician

Accreditation Period

Course opens: 
03/01/2018
Course expires: 
02/28/2019
Please login or register to take this course.